Provectus Biopharmaceuticals Inc (PVCT)

[Gulfbreeze]

New addition to PVCT's Strategic Advisory Board
Provectus Biopharmaceuticals : Appoints Christopher Kaplan to Its Strategic Advisory Board

09/22/2014 | 06:03am US/Eastern

Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it has appointed Christopher Kaplan to its Strategic Advisory Board effective immediately.

Mr. Kaplan is currently President of Cajetan, LLC, an independent healthcare consulting firm working with companies to deliver better value for patients, fuel innovation, enhance the impact and execution of marketing and sales initiatives, and reduce the cost and complexity of operating systems.

Prior to Cajetan, Mr. Kaplan spent two years with Boehringer Ingelheim as Senior Vice President and Chief Marketing Officer. That followed 12 years at Novartis in both the US and Europe. Mr. Kaplan began at Novartis as Global Head Cardiovascular and Metabolic Business Franchise in Basel Switzerland, moved to Head Nordic Region Cluster and General Manager in Stockholm Sweden, then Head of Northern and Central Europe and Region Europe Marketing & Sales back in Basel. He returned to the US as President, Cardiovascular & Metabolic Operating Unit, E. Hanover New Jersey, and then President and General Manager of the East Operating Unit, also in E. Hanover.

Mr. Kaplan started his pharmaceutical career at Bristol-Myers Squibb Company. He moved quickly through various roles in US sales and sales management and then in US marketing. He began his international experience in Paris as the CV Marketing Director for Europe and then progressed to his last role at Bristol-Myers Squibb as Marketing and Sales Director in Rome, Italy.

Mr. Kaplan is a graduate of Columbia University, holds a Masters of Science Degree from the University of Pennsylvania, and undertook post-graduate studies at INSEAD, Fontainebleu, France. He has also completed executive education programs at Harvard, Wharton and the London Business School.

Dr. Craig Dees, PhD, CEO of Provectus, said, "Chris has a formidable resume and proven track record of success in pharmaceutical sales and marketing. His experience in international business is clearly going to be an asset to Provectus, and I expect his dedication to healthcare innovation and delivery to be equally valuable.”

Mr. Kaplan said, “I am very pleased to be joining the Provectus Strategic Advisory Board at this exciting time in the Company’s development. I am impressed with the science that stands behind PV-10 as well as its prospects for regulatory approval.”